舌口腔咽喉頭領域の炎症に対するアズノ-ル・ミニトロ-チの試用経験

概要

論文の詳細を見る
Clinical study of Azulen® "mini-troche" was carried out in 40 patients, with tongue, oral, pharyngeal and laryngeal inflammations in the mucosa of gingivobuccal sulcus, ten of which were lost to follow up.The effects of Azulen® "mini-troche" was as follows: for 30 cases excellent 5 (17%), good 10 (33%), poor 10 (33%), and none 5 (17%); for tongue and oral inflammation in 6 cases, excellent 1 (16%), good 0, poor 4 (67%), and none 1 (16%); for pharyngeal inflammation in 11 cases, excellent 1 (9%), good 4 (36%), poor 3 (27%), and none 3 (27%), including radiation injuries 1 excellent and another good; for laryngeal inflammation in 9 cases, excellent 2 (22%), good 4 (44%), poor 2 (22%), and none 1 (11%); for pharyngolaryngeal inflammation in 4 cases, excellent 1 (25%), good 2 (50%), poor 1 (25%), and none 0. For acute inflammation in 12 cases, excellent 3 (25%), good 7 (58%), poor 2 (16%), and none 0, for chronic inflammation in 18 cases, excellent 2 (11%), good 3 (16%), poor 8 (44%), and none 5 (27%). Subjective side effects were not complained of.Azulen® "mini-troche" appears safe and useful in upper respiratory inflammations, especially in pharyngeal and laryngeal inflammations, and radiation inflammations.
耳鼻咽喉科臨床学会の論文